卫宁健康(300253) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥456,651,232.19, a decrease of 33.78% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥123,416,298.18, representing a decline of 199.16% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥127,696,752.02, down 205.67% from the previous year[5]. - The company reported a 32.27% decline in operating income due to a decrease in business scale and strategic adjustments[10]. - For the period of January to September 2025, the company achieved operating revenue of 1,295.80 million yuan, a year-on-year decrease of 32.27%[17]. - The net profit attributable to shareholders was -241.39 million yuan, down 256.10% year-on-year, while the net profit after deducting non-recurring gains and losses was -227.52 million yuan, a decline of 259.86%[17]. - The company reported a net profit loss of CNY 247,760,106.95 for the current period, compared to a net profit of CNY 137,443,786.79 in the previous period, indicating a significant decline in profitability[27]. - Operating profit for the current period was CNY -262,980,436.31, a decrease from CNY 124,405,758.13 in the previous period, reflecting operational challenges[27]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was -¥10,839,721.60, showing an increase of 89.58% compared to the same period last year[5]. - The net cash flow from operating activities was -10.84 million yuan, an increase of 89.58% year-on-year[17]. - Cash and cash equivalents at the end of the period were ¥1,224,195,228.21, down from ¥1,335,869,809.86 at the beginning of the period, a decrease of 8.4%[22]. - Total assets at the end of the reporting period were ¥8,345,968,353.30, a decrease of 4.69% from the end of the previous year[5]. - Total assets decreased to ¥8,345,968,353.30 from ¥8,756,485,456.90, a decline of 4.7%[24]. - The company experienced a net cash outflow from operating activities of CNY -10,839,721.60, an improvement from CNY -104,007,374.13 in the previous period[28]. - Cash and cash equivalents at the end of the period totaled CNY 1,151,734,573.86, an increase from CNY 686,882,894.56 in the previous period[29]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 117,280[12]. - The top 10 unrestricted shareholders collectively hold 423,802,370 shares, accounting for 19.14% of the total share capital[13]. - Liu Ning and Hou Minghua together hold 140,627,616 shares, representing 6.35% of the total share capital[13]. - The total number of shares held by the 10 private equity products managed by Shanghai Ying Shui Investment Management Co., Ltd. is 77,749,000 shares, which is 3.51% of the total share capital[13]. - The company has a total of 300,142,261 shares under lock-up, with 299,745,811 shares held by directors and executives[16]. - The company has not reported any changes in the lending or borrowing of shares by the top 10 shareholders due to transfer and financing activities[14]. - The company’s major shareholders include Zhou Wei and Wang Ying, who are the actual controllers[13]. - Zhou Wei holds 132,355,681 shares under lock-up as a director[16]. - The total number of shares held by Sun Jia Ming increased to 2,001,292 after the release of 186,750 shares from lock-up[16]. Revenue Breakdown - The revenue from the medical health information business was 1,191.24 million yuan, a decrease of 25.71%, accounting for 91.93% of total revenue[17]. - The core product software sales and technical service revenue was 1,098.48 million yuan, down 22.78%, representing 84.77% of total revenue[17]. - The internet health business revenue fell to 104.56 million yuan, a decline of 66.24%, making up 8.07% of total revenue[17]. - Total revenue for the period was ¥1,295,802,097.22, a decrease of 32.3% compared to ¥1,913,315,732.46 in the previous period[26]. Investment and Innovation - The company confirmed government subsidies totaling 78.49 million yuan, approximately 89.30% of the audited net profit attributable to shareholders for 2024[20]. - The company received 24 invention patents during the reporting period, enhancing its intellectual property portfolio[20]. - The company holds a total of 81 invention patents, 11 utility model patents, and 212 design patents as of September 30, 2025[21]. - The company incurred research and development expenses of CNY 240,826,375.62, an increase from CNY 209,221,376.53 in the previous period, highlighting a focus on innovation[27]. - The company plans to focus on its core business and increase technological innovation to support clients in digital hospital construction[18]. - The company maintains confidence in its future development despite current challenges, citing strong core customer demand and competitive product advantages[18]. Cost Management - Total operating costs amounted to ¥1,538,894,486.85, down from ¥1,775,372,358.90, reflecting a reduction of 13.3%[26]. - The company reported a decrease in sales expenses to CNY 205,661,234.39 from CNY 238,374,207.49 in the previous period, indicating cost control measures[27].